相似文献
1
NSAIDs: the emperor's new dogma?
Gut. 2003 Sep;52(9):1376-8. doi: 10.1136/gut.52.9.1376.
2
COX-2-Selective NSAIDs: new and improved?
JAMA. 2000 Sep 13;284(10):1297-9. doi: 10.1001/jama.284.10.1297.
3
New dogmas or old?
Gut. 2003 Sep;52(9):1379-81. doi: 10.1136/gut.52.9.1379.
4
Cox-2 inhibitors and other nonsteroidal anti-inflammatory drugs in the treatment of pain in the elderly.
Clin Geriatr Med. 2001 Aug;17(3):489-502, vi. doi: 10.1016/s0749-0690(05)70082-3.
5
[Non-steroidal anti-inflammatory drugs and cyclooxygenase-2-specific inhibitors].
Wien Med Wochenschr. 1999;149(19-20):541-5.
6
Do cyclooxygenase-2 inhibitors provide benefits similar to those of traditional nonsteroidal anti-inflammatory drugs, with less gastrointestinal toxicity?
Ann Intern Med. 2000 Jan 18;132(2):134-43. doi: 10.7326/0003-4819-132-2-200001180-00008.
7
Efficacy of cyclooxygenase-2-specific inhibitors.
Am J Med. 2001 Feb 19;110 Suppl 3A:6S-12S. doi: 10.1016/s0002-9343(00)00681-1.
8
Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study.
JAMA. 2000 Sep 13;284(10):1247-55. doi: 10.1001/jama.284.10.1247.
9
Mechanisms of nonsteroidal anti-inflammatory drug-induced gastrointestinal injury and repair: a window of opportunity for cyclooxygenase-inhibiting nitric oxide donors.
Can J Gastroenterol. 2004 Apr;18(4):229-36. doi: 10.1155/2004/890585.
10
Biochemically based design of cyclooxygenase-2 (COX-2) inhibitors: facile conversion of nonsteroidal antiinflammatory drugs to potent and highly selective COX-2 inhibitors.
Proc Natl Acad Sci U S A. 2000 Jan 18;97(2):925-30. doi: 10.1073/pnas.97.2.925.
引用本文的文献
1
A Review of Anti-Inflammatory Drug-Induced Gastrointestinal Injury: Focus on Prevention of Small Intestinal Injury.
Pharmaceuticals (Basel). 2010 Apr 20;3(4):1187-1201. doi: 10.3390/ph3041187.
2
Latest concepts on the association between nonsteroidal anti-inflammatory drug-induced small intestinal injury and intestinal bacterial flora.
Clin J Gastroenterol. 2013 Oct;6(5):345-51. doi: 10.1007/s12328-013-0424-8. Epub 2013 Sep 20.
3
The impact of non-steroidal anti-inflammatory drugs on the small intestinal epithelium.
J Clin Biochem Nutr. 2014 Jan;54(1):2-6. doi: 10.3164/jcbn.13-84. Epub 2013 Dec 18.
4
[NSAID-colonopathy].
Pathologe. 2006 Feb;27(1):65-72. doi: 10.1007/s00292-005-0810-1.
5
Strictures, diaphragms, erosions or ulcerations of ischemic type in the colon should always prompt consideration of nonsteroidal anti-inflammatory drug-induced lesions.
World J Gastroenterol. 2005 Oct 7;11(37):5828-33. doi: 10.3748/wjg.v11.i37.5828.
6
Gastroprotective action of glucocorticoid hormones during NSAID treatment.
Inflammopharmacology. 2005;13(1-3):27-43. doi: 10.1163/156856005774423746.
7
Is no NSAID a good NSAID? Approaches to NSAID-associated upper gastrointestinal disease.
Curr Gastroenterol Rep. 2004 Dec;6(6):447-53. doi: 10.1007/s11894-004-0066-6.
8
New dogmas or old?
Gut. 2003 Sep;52(9):1379-81. doi: 10.1136/gut.52.9.1379.
本文引用的文献
1
Lack of cardioprotective effect of naproxen.
Arch Intern Med. 2002;162(22):2637; author reply 2638-9. doi: 10.1001/archinte.162.22.2637.
2
Comparison of rofecoxib, celecoxib, and naproxen on renal function in elderly subjects receiving a normal-salt diet.
Clin Pharmacol Ther. 2002 Jul;72(1):50-61. doi: 10.1067/mcp.2002.126182.
3
COX-1 and 2, intestinal integrity, and pathogenesis of nonsteroidal anti-inflammatory drug enteropathy in mice.
Gastroenterology. 2002 Jun;122(7):1913-23. doi: 10.1053/gast.2002.33647.
4
Differential effect of FR122047, a selective cyclo-oxygenase-1 inhibitor, in rat chronic models of arthritis.
Br J Pharmacol. 2002 Feb;135(3):782-8. doi: 10.1038/sj.bjp.0704511.
5
Cyclooxygenase-2--10 years later.
J Pharmacol Exp Ther. 2002 Feb;300(2):367-75. doi: 10.1124/jpet.300.2.367.
6
Inflammatory bowel disease and spondylarthropathy.
Arthritis Rheum. 2001 Dec;44(12):2728-36. doi: 10.1002/1529-0131(200112)44:12<2728::aid-art459>3.0.co;2-8.
7
Effects of specific inhibition of cyclo-oxygenase-1 and cyclo-oxygenase-2 in the rat stomach with normal mucosa and after acid challenge.
Br J Pharmacol. 2001 Apr;132(7):1565-73. doi: 10.1038/sj.bjp.0703955.
8
Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group.
N Engl J Med. 2000 Nov 23;343(21):1520-8, 2 p following 1528. doi: 10.1056/NEJM200011233432103.
9
COX-2 inhibition with rofecoxib does not increase intestinal permeability in healthy subjects: a double blind crossover study comparing rofecoxib with placebo and indomethacin.
Gut. 2000 Oct;47(4):527-32. doi: 10.1136/gut.47.4.527.
10
NSAID-induced gastric damage in rats: requirement for inhibition of both cyclooxygenase 1 and 2.
Gastroenterology. 2000 Sep;119(3):706-14. doi: 10.1053/gast.2000.16510.
Zotero 插件